Mifepristone (RU486), the first clinically available antiprogestin, has generated great interest since its discovery in the early 1980s. Today, it is recognized that mifepristone, along with other antiprogestins, has a potentially significant therapeutic role in human health and disease, with likely applicability to a variety of pregnancy-related conditions (e.g., management of labor) and to contraception, endometriosis, and cancer, among others. But because mifepristone has been studied and used most widely as a means of nonsurgical abortion, political issues have thus far limited research on the drug and prevented its introduction into the U.S. market. This book provides an unbiased evaluation of current knowledge about both the fundamental nature of antiprogestins as well as their possible use in treating numerous diseases and conditions, and it contains recommendations for future research.
Molla S. Donaldson, Laneta Dorflinger, Sarah S. Brown, and Leslie Z. Benet, Editors; Committee on Antiprogestins: Assessing the Science, Institute of Medicine
1 Front Matter; 2 Summary; 3 INtroduction; 4 Uses of Antiprogestins: The Reproductive Cycle (Part I); 5 Uses of Antiprogestins: The Reproductive Cycle (Part II); 6 Other Therapeutic Uses of Antiprogestins; 7 Antiglucocorticoid Effects of Antiprogestins; 8 Animals as Models for Studying Antiprogestins; 9 Appendix A: Agenda fr the IOM Workshop 'Antiprogestins: Assessing the Science'; 10 Appendix B: Background Papers and Presentations (In Order of Presentation at IOM Workshop); 11 B1. 1993: RU 486--A Decade on Today and Tomorrow; 12 B2. Overview and Background: Mechanism of Action of Antiprogestins; 13 B3. The Use of Antiprogestins in the Reproductive Cycle; 14 B4. Potential Contraceptive Effects of Antigestogens; 15 B5. Use of Antiprogestins Before 63 Days of Amenorrhea; 16 B6. Uses of Antiprogestins After 63 Days of Amenorrhea; 17 B7. Comments on Session II; 18 B8. Use of Antiprogestins in the Management of Endometriosis and Leiomyoma; 19 B9. Antiprogestins and the Treatment of Breast Cancer; 20 B10. Uses of RU 486 as an Antiglucocoticoid; 21 B11. Primate Models for the Study of Antiprogestins in Reproductive Medicine; 22 B12. ANtiprogestogens: Perspectives from a Global Research Program; 23 Appendix C: Observers at the Workshop on Antiprogestins; 24 Index
National Research Council, Division of Behavioral and Social Sciences and Education, Institute of Medicine, and Families Board on Children, Youth, Steve Olson
Institute of Medicine, Board on the Health of Select Populations, and Transgender Health Issues and Research Gaps and Opportunities Committee on Lesbian, Gay, Bisexual
Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health
Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb
National Research Council, Institute of Medicine, Board on Life Sciences, Medical Follow-up Agency, and Acquisition of Medical Countermeasures Against Biological Warfare Agents Committee on Accelerating the Research, Development, Leslie Z. Benet, Jane S. Durch, Lois M. Joellenbeck
Institute of Medicine, Division of Health Care Services, Committee to Design a Strategy for Quality Review and Assurance in Medicare, Kathleen N. Lohr, Jo Harris-Wehling, Molla S. Donaldson